. Author manuscript; available in PMC: 2010 Sep 2.

Published in final edited form as: Anticancer Drugs. 2010 Aug;21(7):716–723. doi: 10.1097/CAD.0b013e32833cb658

Table 8.

Mean (±SD) of pharmacokinetic parameters of edotecarin after 1-h

Parameter	Edotecarin
Parameter	Cycle 1	Cycle 2
C_max (ng/ml)^a	79.0 ± 17.6	59.2± 27.3
Dose normalized C_max (ng/ml)^b	13.2 ± 2.9	10.1 ± 4.4
T_max (h)	0.48 ± 0.22	0.83 ± 0.0
AUC (0–24) (ng/h/ml)^a	91.0 ± 21.6	65.3 ± 22.9
Dose normalized AUC (0–24) (h/ng/ml)^b	15.3 ± 3.6	11.1 ± 3.7
AUC (0-inf) (ng/h/ml)^a	124.5 ± 34.7	91.7 ± 31.9
Dose normalized AUC (0-inf) (ng/h/ml/)^b	20.7 ± 5.4	15.4 ± 5.1
CL (l/h/m²)	51.3 ± 12.4	73.3± 29.7
V_ss (l/m²)	884.4 ± 296.0	1408.7± 999.7
T (h)	25.3 ± 6.4	20.3 ± 4.2

AUC, area under the plasma concentration–time curve; CL, total body-clearance; C_max, peak plasma concentration; t, half-life; t_max, time to maximum concentration.

Parameter following the 6 mg/m² dose only.

Normalized to a 1 mg/m² dose.